Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Research article

Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis

Authors: Jiatong Li, Bing Chen, Caifeng Gao, Jing Huang, Yongmei Wang, Shiyin Zhang, Ying Xu, Wenkai Guo, Rong Wang

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

The goal of this study was to investigate the clinical and pathological features and prognosis of idiopathic membranous nephropathy (IMN) with focal segmental lesions.

Methods

In our hospital, 305 patients with nephrotic syndrome confirmed as IMN by renal biopsy were divided into a non-focal segmental lesion group (FSGS- group) and a focal segmental glomerulosclerosis (FSGS) group (FSGS+ group) and retrospectively analyzed. In all, 180 patients were followed for periods ranging from 6 months to 2 years. The general clinicopathological data of both groups were compared, and the effects of different treatment schemes on the prognosis of both groups were observed.

Results

The FSGS+ group had a longer disease course, higher blood pressure levels, and higher serum creatinine and β2-microglobulin levels than did the FSGS- group (all P < 0.05). Pathologically, the FSGS+ group had increased glomerular sclerosis, glomerular mesangial hyperplasia, and acute and chronic tubular lesion rates (all P < 0.05). The remission rate was lower in the FSGS+ group than in the FSGS- group (64.7% vs 82.2%) and, among patients in the FSGS+ group, was lower in patients treated with calmodulin inhibitors than in those treated with cyclophosphamide (P < 0.01). Survival analysis showed that the FSGS+ group had a poor prognosis (χ2 = 4.377, P = 0.036), and risk factor analysis suggested that age at renal biopsy (P = 0.006), 24-h urinary protein quantity (P = 0.01), chronic tubulointerstitial lesions (P = 0.055), and FSGS lesions (P = 0.062) were risk factors for worsening renal condition; furthermore, 24-h urinary protein quantity was an independent risk factor for worsening renal condition.

Conclusions

Membranous nephropathy with FSGS is a risk factor, but not an independent risk factor, for IMN. Patients with membranous nephropathy with FSGS often present hypertension and tubule injury. The nonselective drug cyclophosphamide is preferred, and calcineurin inhibitors should be used with caution.
Literature
1.
go back to reference Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. 2015;385(9981):1983–92.PubMedCrossRef Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. 2015;385(9981):1983–92.PubMedCrossRef
2.
go back to reference Ronco P, Debiec H. Membranous nephropathy: a fairy tale for immunopathologists, nephrologists and patients. Mol Immunol. 2015;68(1):57–62.PubMedCrossRef Ronco P, Debiec H. Membranous nephropathy: a fairy tale for immunopathologists, nephrologists and patients. Mol Immunol. 2015;68(1):57–62.PubMedCrossRef
4.
go back to reference Obrisca B, Ismail G, Jurubita R, Baston C, Andronesi A, Mircescu G. Antiphospholipase A2 receptor autoantibodies: a step forward in the management of primary membranous nephropathy. Biomed Res Int. 2015;2015:249740.PubMedPubMedCentralCrossRef Obrisca B, Ismail G, Jurubita R, Baston C, Andronesi A, Mircescu G. Antiphospholipase A2 receptor autoantibodies: a step forward in the management of primary membranous nephropathy. Biomed Res Int. 2015;2015:249740.PubMedPubMedCentralCrossRef
5.
go back to reference Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697–704.PubMedPubMedCentralCrossRef Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697–704.PubMedPubMedCentralCrossRef
6.
go back to reference SHIIKI H, SAITO T, NISHITANI Y, MITARAI T, YORIOKA N, YOSHIMURA A, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400–7.PubMedCrossRef SHIIKI H, SAITO T, NISHITANI Y, MITARAI T, YORIOKA N, YOSHIMURA A, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400–7.PubMedCrossRef
7.
go back to reference Dumoulin A, Hill GS, Montseny JJ, Meyrier A. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Am J Kidney Dis. 2003;41(1):38–48.PubMedCrossRef Dumoulin A, Hill GS, Montseny JJ, Meyrier A. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Am J Kidney Dis. 2003;41(1):38–48.PubMedCrossRef
8.
go back to reference Wakai S. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int. 1992;41:428–34.PubMedCrossRef Wakai S. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int. 1992;41:428–34.PubMedCrossRef
9.
go back to reference van de Logt AE, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018;93(4):1016–7.PubMedCrossRef van de Logt AE, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018;93(4):1016–7.PubMedCrossRef
10.
go back to reference Zuo K, Wu Y, Li SJ, Xu F, Zeng CH, Liu ZH. Long-term outcome and prognostic factors of idiopathic membranous nephropathy in the Chinese population. Clin Nephrol. 2013;79(6):445–53.PubMedCrossRef Zuo K, Wu Y, Li SJ, Xu F, Zeng CH, Liu ZH. Long-term outcome and prognostic factors of idiopathic membranous nephropathy in the Chinese population. Clin Nephrol. 2013;79(6):445–53.PubMedCrossRef
11.
go back to reference Chen Y, Tang L, Feng Z, Cao X, Sun X, Liu M, et al. Pathological predictors of renal outcomes in nephrotic idiopathic membranous nephropathy with decreased renal function. Ital Soc Nephrol. 2014;27(3):307–16. Chen Y, Tang L, Feng Z, Cao X, Sun X, Liu M, et al. Pathological predictors of renal outcomes in nephrotic idiopathic membranous nephropathy with decreased renal function. Ital Soc Nephrol. 2014;27(3):307–16.
12.
go back to reference Bazzi C, Usui T, Rizza V, Casellato D, Gallieni M, Nangaku M. Urinary N-acetyl-beta-glucosaminidase and estimated glomerular filtration rate may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy. Nephrology (Carlton). 2018;23(2):175–82.CrossRef Bazzi C, Usui T, Rizza V, Casellato D, Gallieni M, Nangaku M. Urinary N-acetyl-beta-glucosaminidase and estimated glomerular filtration rate may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy. Nephrology (Carlton). 2018;23(2):175–82.CrossRef
13.
go back to reference Gupta R, Sharma A, Mahanta PJ, Jacob TG, Agarwal SK, Roy TS, et al. Focal segmental glomerulosclerosis in idiopathic membranous glomerulonephritis: a clinico-pathological and stereological study. Nephrol Dial Transplant. 2010;25(2):444–9.PubMedCrossRef Gupta R, Sharma A, Mahanta PJ, Jacob TG, Agarwal SK, Roy TS, et al. Focal segmental glomerulosclerosis in idiopathic membranous glomerulonephritis: a clinico-pathological and stereological study. Nephrol Dial Transplant. 2010;25(2):444–9.PubMedCrossRef
14.
go back to reference Heeringa SF, Branten AJ, Deegens JK, Steenbergen E, Wetzels JF. Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy. Nephrol Dial Transplant. 2007;22(8):2201–7.PubMedCrossRef Heeringa SF, Branten AJ, Deegens JK, Steenbergen E, Wetzels JF. Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy. Nephrol Dial Transplant. 2007;22(8):2201–7.PubMedCrossRef
15.
go back to reference Gu QH, Cui Z, Huang J, Zhang YM, Qu Z, Wang F, et al. Patients with combined membranous nephropathy and focal segmental Glomerulosclerosis have comparable clinical and autoantibody profiles with primary membranous nephropathy: a retrospective observational study. Medicine (Baltimore). 2016;95(21):e3786.CrossRef Gu QH, Cui Z, Huang J, Zhang YM, Qu Z, Wang F, et al. Patients with combined membranous nephropathy and focal segmental Glomerulosclerosis have comparable clinical and autoantibody profiles with primary membranous nephropathy: a retrospective observational study. Medicine (Baltimore). 2016;95(21):e3786.CrossRef
16.
go back to reference Troyanov Se A, Wall CA, Miller JW, Scholey JC, Cattran D. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2014;66:1199–205.CrossRef Troyanov Se A, Wall CA, Miller JW, Scholey JC, Cattran D. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2014;66:1199–205.CrossRef
17.
go back to reference Laluck BJ, Cattran DC. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis. 1999;33(6):1026–32.PubMedCrossRef Laluck BJ, Cattran DC. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis. 1999;33(6):1026–32.PubMedCrossRef
18.
go back to reference Praga M, Barrio V, Juarez GF, Luno J. Grupo Espanol de Estudio de la Nefropatia M. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924–30.PubMedCrossRef Praga M, Barrio V, Juarez GF, Luno J. Grupo Espanol de Estudio de la Nefropatia M. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924–30.PubMedCrossRef
19.
go back to reference Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011;179(4):1719–32.PubMedPubMedCentralCrossRef Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011;179(4):1719–32.PubMedPubMedCentralCrossRef
20.
go back to reference Winn MP. 2007 young investigator award: TRP'ing into a new era for glomerular disease. J Am Soc Nephrol. 2008;19(6):1071–5.PubMedCrossRef Winn MP. 2007 young investigator award: TRP'ing into a new era for glomerular disease. J Am Soc Nephrol. 2008;19(6):1071–5.PubMedCrossRef
21.
go back to reference Li ZQ, Hu ML, Zhang C, Wang YM. Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: a meta-analysis of Chinese adults. J Huazhong Univ Sci Technolog Med Sci. 2015;35(5):623–8.PubMedCrossRef Li ZQ, Hu ML, Zhang C, Wang YM. Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: a meta-analysis of Chinese adults. J Huazhong Univ Sci Technolog Med Sci. 2015;35(5):623–8.PubMedCrossRef
22.
go back to reference Feutren C. J. Mihatsch M. risk factors for cyclosporine induced nephropathy in patients with autoimmune diseases. N Engl J Med. 1992;329(25):1654–60.CrossRef Feutren C. J. Mihatsch M. risk factors for cyclosporine induced nephropathy in patients with autoimmune diseases. N Engl J Med. 1992;329(25):1654–60.CrossRef
24.
go back to reference Nagata M, Kobayashi N, Hara S. Focal segmental glomerulosclerosis; why does it occur segmentally? Pflugers Arch. 2017;469(7–8):983–8.PubMedCrossRef Nagata M, Kobayashi N, Hara S. Focal segmental glomerulosclerosis; why does it occur segmentally? Pflugers Arch. 2017;469(7–8):983–8.PubMedCrossRef
25.
go back to reference Meyrier A. Treatment of focal segmental glomerulosclerosis. Expert Opin Pharmacother. 2005;6(9):1539–49.PubMedCrossRef Meyrier A. Treatment of focal segmental glomerulosclerosis. Expert Opin Pharmacother. 2005;6(9):1539–49.PubMedCrossRef
Metadata
Title
Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis
Authors
Jiatong Li
Bing Chen
Caifeng Gao
Jing Huang
Yongmei Wang
Shiyin Zhang
Ying Xu
Wenkai Guo
Rong Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1641-2

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.